The initiation of coverage with a Buy rating and a price target of $10 by a reputable analyst firm like HC Wainwright & Co. is likely to positively impact the stock price of Cognition Therapeutics in the short term. This is because such ratings often attract investor interest and can lead to increased buying activity.